Recommendations for the management of patients with diabetes and acute or chronic coronary syndromes
 |
|
Recommendations on glucose targets are outlined in section 6.2.1. Recommendations on glucose-lowering drugs for DM are outlined in section 7.1.2.
ACEI = angiotensin-converting enzyme inhibitor; ACS = acute coronary syndromes; ARB = angiotensin receptor blocker; b.i.d. = twice daily (bis in die); CABG = coronary artery bypass graft; CAD = coronary artery disease; CCS = chronic coronary syndromes; CV = cardiovascular; DAPT = dual antiplatelet therapy; DM = diabetes mellitus; eGFR = estimated glomerular filtration rate; PCI = percutaneous coronary intervention.
Class of recommendation.
Level of evidence.
Full-dose clopidogrel or reduced-dose ticagrelor (60 mg b.i.d.).
Prior history of intracerebral haemorrhage or ischaemic stroke, history of other intracranial pathology, recent gastrointestinal bleeding or anaemia due to possible gastrointestinal blood loss, other gastrointestinal pathology associated with increased bleeding risk, liver failure, bleeding diathesis or coagulopathy, extreme old age or frailty, or renal failure requiring dialysis or with eGFR <15 mL/min/1.73 m2.
Recommendations for the management of patients with diabetes and acute or chronic coronary syndromes
|
|
Recommendations on glucose targets are outlined in section 6.2.1. Recommendations on glucose-lowering drugs for DM are outlined in section 7.1.2.
ACEI = angiotensin-converting enzyme inhibitor; ACS = acute coronary syndromes; ARB = angiotensin receptor blocker; b.i.d. = twice daily (bis in die); CABG = coronary artery bypass graft; CAD = coronary artery disease; CCS = chronic coronary syndromes; CV = cardiovascular; DAPT = dual antiplatelet therapy; DM = diabetes mellitus; eGFR = estimated glomerular filtration rate; PCI = percutaneous coronary intervention.
Class of recommendation.
Level of evidence.
Full-dose clopidogrel or reduced-dose ticagrelor (60 mg b.i.d.).
Prior history of intracerebral haemorrhage or ischaemic stroke, history of other intracranial pathology, recent gastrointestinal bleeding or anaemia due to possible gastrointestinal blood loss, other gastrointestinal pathology associated with increased bleeding risk, liver failure, bleeding diathesis or coagulopathy, extreme old age or frailty, or renal failure requiring dialysis or with eGFR <15 mL/min/1.73 m2.
